1. Home
  2. REVB vs CPHI Comparison

REVB vs CPHI Comparison

Compare REVB & CPHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • REVB
  • CPHI
  • Stock Information
  • Founded
  • REVB 2020
  • CPHI N/A
  • Country
  • REVB United States
  • CPHI China
  • Employees
  • REVB N/A
  • CPHI N/A
  • Industry
  • REVB Biotechnology: Pharmaceutical Preparations
  • CPHI Biotechnology: Pharmaceutical Preparations
  • Sector
  • REVB Health Care
  • CPHI Health Care
  • Exchange
  • REVB Nasdaq
  • CPHI Nasdaq
  • Market Cap
  • REVB 4.4M
  • CPHI 4.7M
  • IPO Year
  • REVB N/A
  • CPHI N/A
  • Fundamental
  • Price
  • REVB $2.87
  • CPHI $1.68
  • Analyst Decision
  • REVB
  • CPHI
  • Analyst Count
  • REVB 0
  • CPHI 0
  • Target Price
  • REVB N/A
  • CPHI N/A
  • AVG Volume (30 Days)
  • REVB 87.7K
  • CPHI 42.8K
  • Earning Date
  • REVB 11-07-2025
  • CPHI 08-14-2025
  • Dividend Yield
  • REVB N/A
  • CPHI N/A
  • EPS Growth
  • REVB N/A
  • CPHI N/A
  • EPS
  • REVB N/A
  • CPHI N/A
  • Revenue
  • REVB N/A
  • CPHI $4,396,201.00
  • Revenue This Year
  • REVB N/A
  • CPHI N/A
  • Revenue Next Year
  • REVB N/A
  • CPHI N/A
  • P/E Ratio
  • REVB N/A
  • CPHI N/A
  • Revenue Growth
  • REVB N/A
  • CPHI N/A
  • 52 Week Low
  • REVB $2.11
  • CPHI $1.20
  • 52 Week High
  • REVB $60.48
  • CPHI $3.35
  • Technical
  • Relative Strength Index (RSI)
  • REVB 56.54
  • CPHI 61.74
  • Support Level
  • REVB $2.65
  • CPHI $1.34
  • Resistance Level
  • REVB $2.88
  • CPHI $1.48
  • Average True Range (ATR)
  • REVB 0.19
  • CPHI 0.10
  • MACD
  • REVB 0.03
  • CPHI 0.03
  • Stochastic Oscillator
  • REVB 88.00
  • CPHI 98.53

About REVB Revelation Biosciences Inc.

Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).

About CPHI China Pharma Holdings Inc.

China Pharma Holding Inc is a drug manufacturing company. It is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People's Republic of China. The company mainly manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The product line of the company includes cefaclor dispersible tablets, clarithromycin granules, roxithromycin dispersible tablets, andrographolide tablets, ozagrel sodium for injection, gastrodin injection and others.

Share on Social Networks: